Fig. 4.

Inhibition of basal and TSAb-induced up-regulation of the expression of thyroperoxidase mRNA in primary cultures of human thyrocytes. NCGC00229600 inhibited the levels by 65 ± 2.0% (mean ± sem). Importantly, although the thyrocytes were exposed to NCGC00229600 for 48 h, there was no evidence of toxicity. [Reproduced from S. Neumann et al.: A new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor. J Clin Endocrinol Metab 96:548–554, 2011 (36), with permission. © The Endocrine Society.]